

2-17-2020

Hemodynamic and Clinical Effects of Selexipag in Children With Pulmonary Hypertension

Abraham Rothman

University of Nevada, Las Vegas, abraham.rothman@unlv.edu

Gabriel Cruz

Tecnologico de Monterrey

William N. Evans

University of Nevada, Las Vegas, william.evans@unlv.edu

Humberto Restrepo

Children's Heart Center Nevada

Follow this and additional works at: https://digitalscholarship.unlv.edu/som_fac_articles



Part of the [Pediatrics Commons](#), and the [Respiratory Tract Diseases Commons](#)

Repository Citation

Rothman, A., Cruz, G., Evans, W. N., Restrepo, H. (2020). Hemodynamic and Clinical Effects of Selexipag in Children With Pulmonary Hypertension. *Pulmonary Circulation*, 10(1), 1-7.

<http://dx.doi.org/10.1177/2045894019876545>

This Article is protected by copyright and/or related rights. It has been brought to you by Digital Scholarship@UNLV with permission from the rights-holder(s). You are free to use this Article in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/or on the work itself.

This Article has been accepted for inclusion in School of Medicine Faculty Publications by an authorized administrator of Digital Scholarship@UNLV. For more information, please contact digitalscholarship@unlv.edu.

Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension

Abraham Rothman^{1,2}, Gabriel Cruz³, William N. Evans^{1,2} and Humberto Restrepo^{1,2} 

¹Children's Heart Center Nevada, Las Vegas, USA; ²University of Nevada Las Vegas, School of Medicine, Department of Pediatrics, Las Vegas, USA; ³Tecnologico de Monterrey, School of Medicine, Monterrey, Mexico

Abstract

Selexipag is an oral prostacyclin receptor agonist; it was recently approved for use in adults with pulmonary arterial hypertension. The safety and efficacy of selexipag has not yet been determined in the pediatric population. We describe short-term hemodynamic and clinical data with selexipag therapy in four pediatric patients with pulmonary hypertension. We reviewed clinical, echocardiographic, and hemodynamic data. One patient was transitioned from subcutaneous treprostinil to selexipag, and in three patients, selexipag was added as a third agent. Drug dosing was attained empirically based on patient body size. A follow-up catheterization was performed 12–18 months after initiation of selexipag therapy. All four patients tolerated selexipag well, without significant side effects. One patient transitioned successfully from subcutaneous treprostinil to selexipag. None of the four patients had clinical deterioration. In three patients who were able to perform a 6-minute walk test, pre and post selexipag distances were 350 and 400, 409 and 390, and 300 and 360 m, respectively. Echocardiograms showed no significant changes. Catheterization showed a variable change in pulmonary vascular resistance (small decrease in three patients and increase in one patient). Brain natriuretic peptide levels before and after selexipag in the four patients were 38 and 49, 33 and 54, 29 and 25, and 12 and 14 pg/mL, respectively. Selexipag use for 16–28 months was safe in four pediatric patients; none of them had clinical deterioration. Larger number of patients and longer follow-up intervals are necessary before further recommendations can be made.

Keywords

cardiac catheterization, pulmonary hypertension, selexipag

Date received: 10 June 2019; accepted: 12 August 2019

Pulmonary Circulation 2020; 10(1) 1–7

DOI: 10.1177/2045894019876545

Introduction

Abnormal vascular smooth muscle cell contractility, proliferation, and migration are important processes in the development of pulmonary arterial hypertension (PAH). Three molecular pathways have been the target of PAH-specific medications, including nitric oxide—cyclic guanosine monophosphate—phosphodiesterase, endothelin receptors, and prostacyclin receptors. The prostacyclin receptor (IP) is a membrane receptor coupled to a G_s type protein, which leads to an increase in cAMP, resulting in vasodilatory and anti-aggregatory effects. IP is also coupled to G_i and G_q proteins, which causes a reduction in vascular smooth muscle cell contraction, proliferation, and migration. Despite a reduction in IP receptor levels in end-stage PAH, the antiproliferative effects of IP receptor agonists

appear to be preserved, with concurrent activation of both the EP4 receptor and the PPAR γ pathway. Data suggest that both IP receptor-dependent and -independent effects are responsible for the antiproliferative effects of prostaglandin analogs.^{1–4}

Selexipag, a selective IP receptor agonist, was approved in December 2015 by the Food and Drug Administration for the treatment of PAH World Health Organization (WHO) Group 1 patients with functional class II or III to delay the disease progression and reduce the risk of

Corresponding author:

Abraham Rothman, Children's Heart Center Nevada, 3006 S. Maryland Pkwy, Ste 690, Las Vegas NV 89109, USA.

Email: arothman@childrensheartcenter.com



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<http://www.creativecommons.org/licenses/by-nc/4.0/>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<https://us.sagepub.com/en-us/nam/open-access-at-sage>).

© The Author(s) 2020.

Article reuse guidelines:
sagepub.com/journals-permissions
journals.sagepub.com/home/pul



hospitalization. Selexipag has a similar mechanism of action as prostacyclin (PGI₂); however, selexipag is a nonprostanoid IP receptor agonist. Selexipag works as a pro-drug. Its active metabolite (ACT-333679) has a 130-fold higher selectivity for the IP receptor than other prostanoid receptors. This high selectivity is probably responsible for the low side effect profile of selexipag compared with the PGI₂ analogs. Moreover, it appears that selexipag does not cause IP receptor desensitization and internalization, which avoids the tachyphylaxis observed with PGI₂ analogs.^{5,6}

There are few published reports on the use of selexipag in the pediatric population.^{7,8} We describe preliminary and short-term hemodynamic (12–18 months) and clinical (16–28 months) data with selexipag use in four pediatric patients, one a former premature infant with chronic lung disease and three with idiopathic PAH.

Case 1

A former 24-week premature infant with a birth weight of 589 g, chronic lung disease, pulmonary hypertension (group 3 PH), and a patent foramen ovale (PFO), underwent a gastrostomy tube and ventriculo-peritoneal shunt placement and revision. He was started on sildenafil. His first cardiac catheterization at 5 months of age (Table 1) revealed suprasystemic pulmonary arterial pressure with a pulmonary vascular resistance indexed (PVRi) of 23.8 Wood units (WU). He was started on subcutaneous treprostinil. A second catheterization at 17 months of age revealed pulmonary arterial pressure at $\frac{3}{4}$ of systemic level with a PVRi of 9.4 WU. At the request of the parents, the treprostinil was discontinued. Bosentan was started. A third catheterization, at 2 years and 9 months of age, showed suprasystemic pulmonary arterial

pressure with a PVRi of 15.2 WU. Subsequent to the procedure, it was recommended to the parents to resume treprostinil, but they remained strongly opposed. His WHO functional class was II. Selexipag was started at 200 mcg (tablet dissolved in water) twice a day, with an increase 2 weeks later to 400 mcg twice a day, and 2 weeks later to 600 mcg twice a day. The parents reported no side effects.

At 3.5 years of age, his liver enzymes were elevated, and he was therefore switched from bosentan to macitentan. Sixteen months after starting selexipag, his weight was 13.4 kg and he was on nightly oxygen, sildenafil 10 mg three times a day, selexipag 600 mcg twice a day, and macitentan 3 mg daily. A cardiac catheterization showed systemic level pulmonary arterial pressure with a PVRi of 13.8 WU. Twelve months later, he continued to do well clinically without adverse effects from the medications. His brain natriuretic peptide (BNP) level was 49 pg/mL, compared with a BNP level of 38 pg/mL prior to starting selexipag. His echocardiogram was unchanged showing good left ventricular (LV) function, moderate right ventricular dilatation with good function, moderate flattening of the interventricular septum in systole and trace tricuspid regurgitation.

Case 2

A girl presented at 11 years of age to the emergency department with dyspnea, saturations in 70s and 80s, a murmur and cardiomegaly on a chest x-ray. An echocardiogram showed severe right-sided cardiac enlargement, moderate tricuspid regurgitation with a peak velocity of 5 m/s, mild to moderate pulmonary regurgitation with a peak velocity of 3.2 m/s, a stretched PFO with right-to-left flow and good LV function. At cardiac catheterization, she developed

Table 1. Summary of hemodynamic and clinical data for patient no.1.

Patient age	Baseline or NO/O ₂	PAp systolic/diastolic (Mean) (mmHg)	AOp systolic/diastolic (Mean) (mmHg)	PVRi (WU)	PVRi/SVRi	Medications	BNP (pg/mL)
5 months	Baseline	85/44 (64)	59/38 (45)	23.8	0.77	Sildenafil	
	NO/O ₂	60/30 (45)	63/41 (52)	16.8	0.81	Start treprostinil	
1 year							38
1 year, 5 months	Baseline	62/15 (38)	80/39 (55)	9.4	0.64		
	NO/O ₂	53/12 (31)	80/42 (54)	7.7	0.47	End treprostinil Start bosentan	
2 years 9 months	Baseline	84/26 (53)	72/43 (52)	15.2	1.0		
	NO/O ₂	83/23 (52)	74/43 (56)	12.6	0.85	Start selexipag End bosentan Start macitentan	
3 years 7 months						Selexipag = 16 months	
4 years 1 month	Baseline	78/23 (49)	79/47 (60)	13.8	0.82		
	NO/O ₂	69/17 (40)	78/45 (59)	10.3	0.64		
4 years 11 months							49

AOp: aortic pressure; Baseline: baseline catheterization; BNP: brain natriuretic peptide; NO: nitric oxide; O₂: oxygen; PAp pulmonary arterial pressure; PVRi: pulmonary vascular resistance indexed; SVRi: systemic vascular resistance indexed; WU: Wood units.

Table 2. Summary of hemodynamic and clinical data for patient no.2.

Patient age	Baseline or NO/O ₂	PAP systolic/diastolic (Mean) (mmHg)	AOP systolic/diastolic (Mean) (mmHg)	PVRi (WU)	PVRi/SVRi	Medications	6-MWT (m)	BNP (pg/mL)
11 years 10 months	Baseline	N/A	N/A	N/A	N/A			
	NO/O ₂	71/40 (53)	72/53 (63)	15.4	1.42	Start sildenafil and treprostinil		
12 years 10 months	Baseline	94/51 (68)	80/51 (64)	24.3	1.2		350	
	NO/O ₂	81/31 (55)	90/48 (64)	13.0	0.8	Start ambrisentan		
13 years 1 month								33
13 years 2 months						End treprostinil		
						Start selexipag		
13 years 10 months							400	
14 years 8 months	Baseline	89/48 (64)	79/49 (62)	22.5	1.1	Selexipag = 18 months		
	NO/O ₂	82/37 (56)	90/54 (52)	14.8	0.71			
15 years 1 month							400	54

AOP: aortic pressure; Base: baseline catheterization; BNP: brain natriuretic peptide; NO: nitric oxide; O₂: oxygen; PAP: pulmonary arterial pressure; PVRi: pulmonary vascular resistance indexed; SVRi: systemic vascular resistance indexed; WU: Wood units; 6-MWT: 6-minute walk test.

significant desaturation and hypotension in room air, so baseline hemodynamics could not be obtained. On oxygen and nitric oxide, she had systemic level pulmonary arterial pressure (Table 2). A diagnosis of severe idiopathic PAH (group 1 PH, WHO functional class II–III) was made. She was started on sildenafil, furosemide, and subcutaneous treprostinil. The patient underwent a second cardiac catheterization a year later, which revealed suprasystemic pulmonary arterial pressure with a PVRi of 24.3 WU. Vasodilator testing with oxygen and nitric oxide resulted in subsystemic pulmonary arterial pressure, with a PVRi of 13 WU.

She was started on ambrisentan. Four months later, the patient was suicidal and requested discontinuing treprostinil (which was at a dose of 40 ng/kg/min). She was transitioned to selexipag over a 4-week period, starting with a dose of 200 mcg twice a day, increasing weekly until she reached 1000 mcg twice a day. Simultaneously, the subcutaneous treprostinil was weaned by 25% a week. The patient reported significant improvement in energy level and exercise tolerance in the ensuing weeks. Eighteen months later, she weighed 58 kg and was on nightly oxygen, sildenafil 20 mg three times a day, selexipag 1000 mg twice a day, and ambrisentan 10 mg daily. At cardiac catheterization, the pulmonary arterial pressure was slightly suprasystemic, with a PVRi of 22.5 WU. Oxygen and nitric oxide administration resulted in subsystemic pulmonary arterial pressure; the PVRi decreased to 14.8 WU. Six months later, the patient was doing well clinically with good exercise tolerance and no symptoms. She carried her backpack at school without difficulties. Her BNP level was 54 pg/mL compared with a BNP level of 33 pg/mL prior to starting selexipag. Her 6-minute walk test (6-MWT) distance 2 years after starting selexipag was 400 m compared with 350 m before starting selexipag.

Case 3

A 2 years and 3 months old girl presented to the emergency department after a syncopal episode with running. An echocardiogram showed a dilated right heart, elevated tricuspid regurgitation velocities, and good LV function. A cardiac catheterization showed slightly suprasystemic pulmonary arterial pressure with a PVRi of 15.6 WU (Table 3). A diagnosis of idiopathic PAH (group 1 PH, WHO functional class II–III) was made and she was started on oxygen at night and sildenafil. Seven months later, she had another syncopal episode with running vigorously and was started on bosentan. A repeat cardiac catheterization at 4 years and 8 months of age showed pulmonary pressures at about 80% of systemic level with a PVRi of 10 WU.

Six months later, she was switched from bosentan to ambrisentan. A cardiac catheterization at 6.5 years showed pulmonary pressures at 72% of systemic level with a PVRi of 9.3 WU. A repeat cardiac catheterization at 8.5 years of age showed slightly subsystemic pulmonary arterial pressure, with a PVRi of 11.5 WU. She was started on selexipag, increasing the dose up to 600 mcg twice a day over 2 weeks. Due to dizziness and decreased activity level, unclear if related to the new medication, the dose was transiently decreased to 400 mcg twice a day, and a few weeks later increased back to 600 mcg twice a day. Twelve months after starting selexipag, she weighed 29 kg and was on nightly oxygen, sildenafil 20 mg three times a day, ambrisentan 5 mg a day, and selexipag 800 mcg twice a day. A catheterization showed subsystemic pulmonary arterial pressure with a PVRi of 15.5 WU. Her BNP level was 25 pg/mL compared with 29 pg/mL prior to starting selexipag. Her 6-minute walk distance was 390 m compared with 409 m prior to starting selexipag. Four months later, the patient was doing well clinically, without significant limitations.

Table 3. Summary of hemodynamic and clinical data for patient no. 3.

Patient age	Baseline or NO/O ₂	PAP systolic/ diastolic (Mean) (mmHg)	AOP systolic/ diastolic (Mean) (mmHg)	PVRi (WU)	PVRi/ SVRi	Medications	6-MWT (m)	BNP (pg/mL)
2 years 3 months	Baseline	83/54 (67)	82/49 (65)	15.6	0.97			
	NO/O ₂	82/43 (61)	86/50 (69)	11.7	0.79	Start sildenafil		
2 years 10 months						Start bosentan		
4 years 8 months	Baseline	72/36 (52)	90/54 (71)	10.0	0.66			
	NO/O ₂	65/25 (43)	88/52 (69)	8.4	0.53			
5 years 3 months						End bosentan		
6 years 7 months	Baseline	70/32 (51)	99/59 (68)	9.3	0.66	Start ambrisentan		
	NO/O ₂	67/28 (46)	84/52 (73)	7.4	0.52			
7 years 2 months								29
8 years 7 months	Baseline	83/41 (60)	94/60 (75)	11.5	0.71		409	
	NO/O ₂	75/33 (52)	91/51 (72)	11.2	0.60	Start selexipag		
9 years 9 months	Baseline	75/37 (55)	83/53 (64)	15.5	0.79	Selexipag = 12 months	390	25
	NO/O ₂	69/28 (46)	86/53 (69)	14.4	0.59			

AOP: aortic pressure; Base: baseline catheterization; BNP: brain natriuretic peptide; NO: nitric oxide; O₂: oxygen; PAP: pulmonary arterial pressure; PVRi: pulmonary vascular resistance indexed; SVRi: systemic vascular resistance indexed; WU: Wood units; 6-MWT: 6-minute walk test.

Table 4. Summary of hemodynamic and clinical data for patient no. 4.

Patient age	Baseline or NO/O ₂	PAP systolic/ diastolic (Mean) (mmHg)	AOP systolic/ diastolic (Mean) (mmHg)	PVRi (WU)	PVRi/ SVRi	Medications	6-MWT (m)	BNP (pg/mL)
1 year 2 months	Baseline	61/25 (42)	87/62 (73)	10.7	0.58			
	O ₂	54/17 (35)	82/57 (68)	6.5	0.29	Start sildenafil		
2 years 5 months	Baseline	102/42 (70)	74/46 (60)	14.5	1.16			
	NO/O ₂	80/29 (50)	90/58 (69)	9.3	0.65	Start bosentan		
9 years 5 months	Baseline	72/18 (42)	87/57 (72)	9.4	0.43			
	NO/O ₂	60/13 (34)	85/53 (68)	7.2	0.32			
12 years 5 months	Baseline	74/22 (48)	91/55 (73)	11.2	0.59			
	NO/O ₂	70/20 (40)	100/55 (75)	8.3	0.43			
14 years 2 months							300	12
14 years 4 months	Baseline	82/42 (62)	77/40 (64)	16.5	1.0			
	NO/O ₂	77/32 (55)	74/45 (52)	13.4	1.1	Start selexipag		
15 years 7 months							360	14
15 years 8 months	Baseline	80/41 (60)	79/57 (66)	13.9	0.86	Selexipag = 15 months		
	NO/O ₂	71/29 (49)	75/55 (65)	10.9	0.48			

AOP: aortic pressure; Baseline: baseline catheterization; BNP: brain natriuretic peptide; NO: nitric oxide; O₂: oxygen; PAP: pulmonary arterial pressure; PVRi: pulmonary vascular resistance indexed; SVRi: systemic vascular resistance indexed; WU: Wood units; 6-MWT: 6-minute walk test.

Case 4

A 14-months-old-girl presented with syncopal episodes. An implantable loop recorder documented asystole of 4.5 s. A computed tomography angiogram showed dilation of right-sided cardiac chambers and the pulmonary arteries. A cardiac catheterization showed subsystemic pulmonary

arterial pressure with a PVRi of 10.7 WU (Table 4). She had a PFO versus small atrial septal defect with left-to-right flow. A diagnosis of idiopathic PAH (group 1 PH) was made, and treatment with sildenafil was started. A cardiac catheterization at 2.5 years of age showed supra-systemic pulmonary arterial pressure, with a PVRi of 14.5 WU. Vasodilator testing with nitric oxide and oxygen

resulted in subsystemic pulmonary arterial pressure. She was started on bosentan.

She did well clinically for several years and underwent catheterizations at 9.5 and 12.5 years of age revealing subsystemic pulmonary arterial pressures. A cardiac catheterization performed at 14 years of age showed slightly suprasystemic pulmonary arterial pressure with a PVRi of 16.5 WU. Her WHO functional class was II. Selexipag was started at a dose of 200 mcg twice a day, increasing the dose weekly up to 1000 mcg twice a day; however, she developed diarrhea and headaches. The dose was decreased transiently to 800 mcg twice a day with resolution of side effects. Fifteen months later, she weighed 67 kg and was on nightly oxygen, sildenafil 20 mg three times a day, bosentan 62.5 mg twice a day, and selexipag 1000 mcg twice a day. A repeat catheterization showed systemic level pulmonary arterial pressure with a PVRi of 13.9 WU. After the administration of oxygen and nitric oxide (20 ppm), the PVRi decreased to 10.9 WU. Her BNP level was 14 pg/mL compared with 12 pg/mL prior to starting selexipag. Her 6-minute walk distance was 360 m compared with 300 m prior to starting selexipag. Four months later, the patient was on selexipag at a dose of 1200 mcg twice a day and was doing well clinically.

Discussion

Pediatric patients with PAH have traditionally been started on one or two drugs, often a phosphodiesterase 5 inhibitor and/or an endothelin receptor antagonist. Patients with severe PAH or disease progression have been treated with intravenous (IV) or subcutaneous prostacyclin analogs. However, the difficulties with drug storage and delivery and significant side effects and complications of the latter have limited their use. The recent approval of an oral prostacyclin receptor agonist, selexipag, has provided a newer option to target this molecular pathway.

The GRIPHON study (NCT01106014)⁹ was a multicenter, phase 3 study, in adult patients (selexipag: n = 574; placebo: n = 582) with symptomatic (WHO class II and III) PAH. Selexipag treatment duration was up to 4.2 years, with a median of 1.4 years. Selexipag reduced the risk of time to first morbidity or mortality event by 40% ($p < 0.0001$). The most frequent adverse effects of selexipag in that and other studies were headache, myalgia, nausea, pain in the jaw, arthralgia, skin irritation, diarrhea, pain in the upper abdomen, and dizziness. Compared with PGI2 analogs, selexipag did not cause significant platelet dysfunction and was noted to cause stronger relaxation of the pulmonary arteries. Bioavailability of selexipag after oral administration was demonstrated to be approximately 50%.^{5,6,9–16}

The first report of a pediatric patient treated with selexipag was a 12-year-old girl with WHO functional class III, right ventricular failure, recurrent syncope, dizziness, and progressive fatigue.⁷ The patient had been previously treated with bosentan and sildenafil with no improvement for

9 months. Selexipag was started and advanced to the maximal dose of 1600 mcg within 10 days. Six months later, the patient had a decrease in PVR, right atrial pressure, right ventricular end-diastolic pressure, right atrial and right ventricular size, recovery of vasoreactivity and improved cardiac index, 6-minute walking distance, functional class, and body weight. Her only side effect was mild to moderate nausea.

The largest reported series of selexipag use in the pediatric age group is from the UCLA Mattel Children's Hospital,⁸ consisting of 10 patients (5 with idiopathic PAH, 4 with congenital heart disease, and 1 with congenital diaphragmatic hernia) with a mean age of 16.5 years. The patients were on a phosphodiesterase 5 inhibitor and an endothelin receptor antagonist; four were on IV treprostinil. The four patients on IV treprostinil were successfully transitioned to oral selexipag. Selexipag was well tolerated, with the most common side effects being headaches, loose stools, and jaw pain. The maximum dose of 1600 mcg was achieved in all but one patient. The patients reported improved energy, stamina, exercise tolerance, and decrease in oxygen requirement. One patient became a candidate for cavopulmonary anastomosis only after starting selexipag. Among 7 of the 10 patients who performed 6-MWT before and after selexipag therapy, 3 had an increase and 4 had a decrease in walk distance. Hemodynamic data were not obtained routinely before or after starting selexipag.

In a recent research letter, Koestenberger and Hansmann¹⁷ briefly summarized their experience using selexipag in nine patients ranging in age from 1.5 to 17 years and weight from 7 to 76 kg. Final doses were 400–1600 mcg twice daily. In three of the nine patients, they noted desaturation of more than 5%. When the dose was decreased by 200 mcg twice daily, the saturations improved, presumably from less intrapulmonary shunting and subsequently lower drug metabolite levels. The most common side effects they observed were nausea, vomiting, flushing, and headache, all of which improved with anti-emetics.

Here, we report hemodynamic data, 6-MWT results, and BNP levels before and 12–18 months after starting selexipag in four pediatric PAH patients. In one patient, selexipag was used as a substitute for subcutaneous treprostinil, in the other three patients it was added as a third agent due to hemodynamic deterioration. Each of the patients did well clinically for 16–28 months after initiating selexipag. Two of the three older patients reported improved exercise tolerance and energy levels in the first few months after starting selexipag; one reported no change. Two patients had transient side effects, which resolved with temporary reduction of the selexipag dose. The maximum dose utilized in each patient was empiric, based on body weight. At cardiac catheterization, PVRi did not change significantly (small decrease in three patients and a small increase in one patient). A 6-MWT could be performed in three of the patients; the walk distance increased slightly in two and decreased slightly in one. BNP levels were in the normal range

(<100 pg/mL) in all four patients before and after selexipag therapy; there was a small decrease in one and a slight increase in three in BNP levels after the selexipag course.

We speculate that with added experience, selexipag could be an alternative for patients who are on subcutaneous or IV prostacyclin analogs and have significant adverse effects with administration or tolerance. The other potential use for selexipag could be as a third agent for WHO class II or III patients who have worsening on a phosphodiesterase inhibitor and an endothelin receptor antagonist. Whether selexipag could be the second agent of initial double therapy or the third agent of initial triple therapy for pediatric PH patients remains to be determined by future studies.

There are limitations to our study. One is the small number of patients, which precludes definitive conclusions about the safety and effectiveness of selexipag in the pediatric age group. In case 1, bosentan was replaced by macitentan while on selexipag, and in case 2, ambrisentan was started on the patient 4 months before selexipag. In these two cases, it is not possible to know whether some of the beneficial effect was from the endothelin receptor antagonist and not selexipag. Also, the follow-up period of 16–28 months was relatively short. In addition, the final selexipag dose attained in each patient may have been suboptimal. A clinical phase 2 study, with about 55 PAH participants aged 12–18 years, has the objective of determining more optimal doses of Selexipag in children with PH. It started enrolling in 2018 and has an estimated study completion date of December 2025 [NCT03492177].¹⁸

In summary, our experience with selexipag for pediatric PH adds to the limited published literature and suggests that selexipag was well tolerated, with minimal side effects that resolved with transient dose reduction. None of the patients showed clinical signs of worsening. Hemodynamic data were generally reassuring. Larger clinical experience and duration of therapy will be necessary to make more definite recommendations regarding the use of selexipag in pediatric patients with PH.

Authors' contribution

Abraham Rothman: Concept, design, analysis, draft, critical revision, approval of final version. Gabriel Cruz, William N. Evans, and Humberto Restrepo: Data acquisition, analysis, critical revision, and approval of final version.

Conflict of interest

The author(s) declare the following conflicts of interest: Rothman reports speaker fee and educational conference support from Actelion Pharmaceuticals. Evans reports educational conference support from Actelion Pharmaceuticals. The other authors declared no conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval

This investigation received approval from the Sunrise Health Institutional Review Board, approval number 8398, and the

study protocol conforms to the principles of the Declaration of Helsinki. We obtained parental informed consent for the invasive procedures.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID iD

Humberto Restrepo  <https://orcid.org/0000-0002-1198-5787>

References

1. Mubarak KK. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. *Respir Med* 2010; 104: 9–21.
2. Falchetti E, Hall SM, Phillips PG, et al. Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2010; 182: 1161–1170.
3. Lai Y, Pullamsetti SS, Dony E, et al. Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension. *Am J Respir Crit Care Med* 2008; 178: 188–196.
4. Gessler T, Seeger W and Schmehl T. Inhaled prostanoids in the therapy of pulmonary hypertension. *J Aerosol Med Pulm Drug Deliv* 2008; 21: 1–12.
5. Scott LJ. Selexipag: First global approval. *Drugs* 2016; 76: 413–418.
6. Bruderer S, Hurst N, Kaufmann P, et al. Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects. *Pharmacology* 2014; 94: 148–156.
7. Geerdink LM, Bertam H and Hansmann G. First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension. *Pulm Circ* 2017; 7: 551–554.
8. Gallotti R, Drigalis-Kim DE, Satou G, et al. Single-center experience using selexipag in a pediatric population. *Pediatr Cardiol* 2017; 38: 1405–1409.
9. Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. *N Engl J Med* 2015; 373: 2522–2533.
10. Furukawa A, Tamura Y, Iwahori H, et al. Successful transition from treprostinil to selexipag in patient with severe pulmonary arterial hypertension. *BMC Pulm Med* 2017; 17(1): 135.
11. Duggan ST, Keam SJ and Burness CB. Selexipag: A review in pulmonary arterial hypertension. *Am J Cardiovasc Drugs* 2017; 17: 73–80.
12. Wolfson AM, Steiger N and Gomberg-Maitland M. New pharmacotherapies for pulmonary hypertension: Where do they fit in? *Curr Hypertens Rep* 2014; 16: 1–496.
13. Kaufmann P, Okubo K, Bruderer S, et al. Pharmacokinetics and tolerability of the novel oral prostacyclin IP receptor agonist selexipag. *Am J Cardiovasc Drugs* 2015; 15: 195–203.
14. Frost AE, Janmohamed M, Fritz J, et al. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in

- pulmonary arterial hypertension: Results from the Transit-1 study. *J Heart Lung Transpl* 2019; 38: 43–50.
15. Kaufmann P, Hurst N, Astruc B, et al. Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist. *Eur J Clin Pharmacol* 2017; 73: 151–156.
 16. Hansmann G. Pulmonary hypertension in infants, children, and young adults. *J Am Coll Cardiol* 2017; 69: 2551–2569.
 17. Koestenberger M and Hansmann G. Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension? *Pulm Circ* 2018; 8: 1–4.
 18. U.S. National Library of Medicine. A clinical study to confirm the doses of selexipag in children with pulmonary arterial hypertension, <http://www.clinicaltrials.gov> (accessed 25 January 2019).